Takashi Takeshita

Has grant

Chief

Kumamoto University Hospital

Japan

Research Interests

Explore related searches

Professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Takashi Takeshita is the Chief at Kumamoto City Hospital in Japan. His research focuses on breast cancer, with recent articles addressing prognostic biomarkers, hormone therapy resistance, and the impact of treatment regimens on patient outcomes. Notable contributions include studies on cell-free DNA sequencing and machine learning-based prognostic models for hormone receptor-positive breast cancer.

Recent Grants

Grant: Close

乳癌の再発転移予測に向けたMRIと半導体PETのバイオマーカーによる微小環境評価

Open Date: 2021-04-01

Close Date: 2024-03-31

Grant: Close

Development of liquid biopsy method for breast cancer clinical application.

Open Date: 2017-04-01

Close Date: 2019-03-31

Articles (10)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (1)

Hiroshi Tada

Associate Professor

Tohoku University

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Takashi Takeshita

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (10)

Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing

Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing

Addressing ESR1 Mutation: A Key Factor in Hormone Therapy Resistance in Breast Cancer

Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer

Prognostic value of the 21-Gene Breast Recurrence Score® assay for hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer: subanalysis from Japan Breast Cancer Research Group-M07 (FUTURE trial)

Development of a Machine Learning-Based Prognostic Model for Hormone Receptor-Positive Breast Cancer Using Nine-Gene Expression Signature

Dexamethasone dose-dependently prevents taxane-associated acute pain syndrome in breast cancer treatment

Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial)

High dose of dexamethasone attenuates docetaxel-induced fluid retention in breast cancer treatment

Impact of systemic dexamethasone dosage on docetaxel-induced oral mucositis in patients with breast cancer

Collaborators (1)

Hiroshi Tada

Make your next move.